RGEN

Repligen Corporation

Price

$167.22

return (12m)

14.59%

p/e

247.26

p/bv

4.86

DIVIDEND YIELD

0.00%

RGEN price

Repligen

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment RGEN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-0.78%

3 months

16.69%

1 year

14.59%

2 years

22.42%

5 years

-35.38%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals RGEN

Valuation

P/E

247.26

Sector -3.34

Industry -3.34

P/BV

4.86

Sector 1.90

Industry 1.90

P/Revenue (PSR)

26.56

Sector 2.02

Industry 2.02

EV/EBITDA

229.68

Sector -219.13

Industry -219.13

EV/EBIT

505.23

Sector -48.17

Industry -48.17

P/EBITDA

59.85

Sector -22.59

Industry -22.59

P/EBIT

138.24

Sector -30.09

Industry -30.09

P/Total Assets

3.48

Sector 1.12

Industry 1.12

P/Net Current Assets

28.34

Sector -9.63

Industry -9.63

P/Working Capital

9.62

Sector -160.04

Industry -160.04

EPS

0.74

Sector -1.78

Industry -1.78

BVPS

37.71

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

52.84%

Sector 41.35%

Industry 41.35%

EBITDA Margin

Sector -17,192.92%

Industry -17,192.92%

EBIT Margin

Sector -4,203,320.32%

Industry -4,203,320.32%

Operating Margin

8.97%

Sector -35.47%

Industry -35.47%

Net Profit Margins

10.74%

Sector -35.90%

Industry -35.90%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

1.97%

Sector -57.36%

Industry -57.36%

ROA

1.41%

Sector -59.44%

Industry -59.44%

ROIC

1.29%

Sector -2,371.64%

Industry -2,371.64%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

9.05

Sector 2.91

Industry 2.91

Net Debt / EBITDA

-5.95

Sector -22.44

Industry -22.44

Net Debt / EBIT

-13.09

Sector -8.34

Industry -8.34

Net Debt / Equity

-0.12

Sector -33,201.77

Industry -33,201.77

Gross Debt / Equity

0.26

Sector -0.85

Industry -0.85

Equity/Assets

0.72

Sector 0.46

Industry 0.46

Liabilities/Assets

0.28

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

-10.42%

Sector -

Industry -

5Y Earnings CAGR

-20.19%

Sector -

Industry -

Fundamentals RGEN

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Repligen ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$167.22

Fair Value

$25.06

Upside

-85.02%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
RGEN Repligen Corporation	$167.22	11.41%	0.00%	247.26	4.86	1.97%	10.74%
PFE Pfizer Inc.	$28.11	13.84%	6.26%	36.14	1.83	5.07%	6.80%
ABBV AbbVie Inc.	$274.45	23.03%	2.63%	72.88	-77.57	-106.44%	9.81%
NVO Novo Nordisk A/S	$38.26	-32.62%	4.98%	9.10	4.83	53.11%	35.32%
MRK Merck & Co. Inc.	$142.79	65.52%	2.36%	110.80	8.37	7.56%	4.77%
AZN AstraZeneca PLC	$161.17	-4.54%	2.06%	18.71	4.82	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$59.70	39.95%	4.20%	13.14	5.46	41.59%	18.87%
ZTS Zoetis Inc.	$71.55	-49.83%	3.01%	11.00	9.21	83.77%	27.69%
AMGN Amgen Inc.	$414.45	44.80%	2.47%	24.84	18.58	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$742.12	32.13%	0.51%	17.33	2.37	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$110.79	65.43%	0.00%	30.90	89.03	288.13%	24.86%
MCK McKesson Corporation	$910.33	23.29%	0.38%	22.96	-27.29	-118.84%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$505.64	25.50%	0.00%	28.87	6.28	21.76%	35.00%
CAH Cardinal Health Inc.	$232.16	51.52%	0.91%	30.94	-19.47	-62.92%	0.67%
ARGX argenx SE	$939.38	19.22%	0.00%	20.47	5.36	26.20%	25.70%
HRMY Harmony Biosciences Holdings Inc.	$39.34	47.95%	0.00%	12.60	2.28	18.14%	18.88%
BIIB Biogen Inc.	$226.46	47.00%	0.00%	38.99	1.73	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

RGEN - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Repligen

Repligen Corporation

Average Investor10 user rating

4.0 (0 people)

United States

45 years

Founded: 1981

1986

Time since IPO - 40 years

761

Employees

Repligen Corporation (United States) is listed on the Nasdaq and has a market capitalization of $10.27 billion, with shareholders equity totaling $2.11 billion.

The company employs approximately 761 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Repligen Corporation reported $386.72 million in revenue, generating net income of $41.54 million.

Key financial metrics include a P/E ratio of 247.26, a price-to-book (P/B) ratio of 4.86, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker RGEN.

Market cap

$10.27 billion

Net worth

$2.11 billion

$2,112,032,000.00

Assets

$2.95 billion

$2,950,180,000.00

Total Shares Outstanding

56.00 million

56,000,000

Average Daily Trading Volume

$1.11 million

$1,106,471.96

Sector

Health Care

Industry

Biotechnology

RGEN

RGEN revenue and profits

Financial Results RGEN

DRAG THE FRAME TO SEE MORE DATA

RGEN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$910.33 20,93% (12M)

P/E

22.96

0.38%

ROE

-118.84%

P/BV

-27.29

CAH - Cardinal Health

$232.16 49,05% (12M)

P/E

30.94

0.91%

ROE

-62.92%

P/BV

-19.47

ABBV - AbbVie

$274.45 22,47% (12M)

P/E

72.88

2.63%

ROE

-106.44%

P/BV

-77.57

MRK - Merck & Co.

$142.79 70,12% (12M)

P/E

110.80

2.36%

ROE

7.56%

P/BV

8.37

AZN - AstraZeneca

$161.17 --3,60% (12M)

P/E

18.71

2.06%

ROE

25.77%

P/BV

4.82

PFE - Pfizer

$28.11 17,16% (12M)

P/E

36.14

6.26%

ROE

5.07%

P/BV

1.83

BMY - Bristol-Myers Squibb

$59.70 41,84% (12M)

P/E

13.14

4.20%

ROE

41.59%

P/BV

5.46

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$910.33 20,93% (12 M)

P/L

22.96

0.38%

ROE

-118.84%

P/VP

-27.29

CAH - Cardinal Health

$232.16 49,05% (12 M)

P/L

30.94

0.91%

ROE

-62.92%

P/VP

-19.47

ABBV - AbbVie

$274.45 22,47% (12 M)

P/L

72.88

2.63%

ROE

-106.44%

P/VP

-77.57

MRK - Merck & Co.

$142.79 70,12% (12 M)

P/L

110.80

2.36%

ROE

7.56%

P/VP

8.37

AZN - AstraZeneca

$161.17 --3,60% (12 M)

P/L

18.71

2.06%

ROE

25.77%

P/VP

4.82

PFE - Pfizer

$28.11 17,16% (12 M)

P/L

36.14

6.26%

ROE

5.07%

P/VP

1.83

BMY - Bristol-Myers Squibb

$59.70 41,84% (12 M)

P/L

13.14

4.20%

ROE

41.59%

P/VP

5.46

Frequently Asked Questions

What is the price of Repligen (RGEN) today?

The current price of Repligen (RGEN) is $167.22. The stock began the year trading around $163.86 and is currently priced at $167.22. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Repligen (RGEN) pay dividends?

Repligen (RGEN) did not pay dividends over the past year.

Is Repligen (RGEN) a good investment?

Repligen (RGEN) is currently trading at $167.22 with a P/E ratio of 247.26. This represents a 24,245% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 14.59%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Repligen (RGEN) stock?

You can buy Repligen (RGEN) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol RGEN and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Repligen (RGEN) yield today?

Over the past month, Repligen (RGEN) has returned -0.78% — 14.59% over the past year, and -35.38% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Repligen (RGEN) today at the current price of $167.22 your total investment would be $16,722.00.

Based on historical performance, the investment would have grown to approximately:

$19,161.74 after 1 year
$10,805.76 after 5 years
$16,722.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

RGEN

Repligen Corporation

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment RGEN

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING RGEN WITH OTHER STOCK

ABOUT Repligen

Repligen Corporation

United States

45 years

1986

761

PROFIT X PRICE RGEN

Financial Results RGEN

RGEN cash flow

Asset, Revenue and Profit Growth - RGEN

RGEN balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions